Skip to the page

Data / Drug companies / Cohance Lifesciences Limited

Cohance Lifesciences Limited: 20 products in the FDA NDC directory, labeler code 76072

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Cohance Lifesciences Limited (labeler code 76072) lists 20 products in the FDA National Drug Code Directory. By type: 20 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on January 22, 2025.

The request: Watch Cohance Lifesciences Limited (FDA labeler code 76072): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
76072
Products in commercial distribution
20
Packages
20
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
March 20, 2015
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients20100%

Products by type

TypeProductsShare
Bulk ingredients20100%

Dosage forms

Dosage formProductsShare
Powder20100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Buspirone hydrochloride (bpn)76072-1020PowderBulk ingredientsJanuary 22, 2025
Maraviroc76072-1019PowderBulk ingredientsJuly 1, 2020
Dapsone76072-1018PowderBulk ingredientsJuly 1, 2019
Apixaban76072-1017PowderBulk ingredientsJuly 1, 2019
Ticagrelor76072-1016PowderBulk ingredientsJuly 1, 2019
Empagliflozin76072-1015PowderBulk ingredientsJuly 1, 2019
Dapagliflozin propanediol monohydrate76072-1014PowderBulk ingredientsJuly 1, 2019
Mirabegron76072-1013PowderBulk ingredientsMarch 27, 2018
Zonisamide76072-1012PowderBulk ingredientsMarch 27, 2018
Atomoxetine hydrochloride76072-1011PowderBulk ingredientsJune 5, 2017
Clozapine76072-1010PowderBulk ingredientsJune 5, 2017
Quetiapine fumarate76072-1009PowderBulk ingredientsJune 5, 2017
Rivaroxaban76072-1008PowderBulk ingredientsJune 5, 2017
Lurasidone hydrochloride76072-1007PowderBulk ingredientsJune 5, 2017
Pirfenidone76072-1006PowderBulk ingredientsMarch 1, 2017
Eslicarbazepine acetate76072-1005PowderBulk ingredientsMay 6, 2016
Memantine hydrochloride76072-1004PowderBulk ingredientsApril 1, 2016
Fluvoxamine maleate76072-1003PowderBulk ingredientsApril 1, 2016
Aripiprazole76072-1002PowderBulk ingredientsApril 1, 2016
Betahistine hydrochloride76072-1001PowderBulk ingredientsMarch 20, 2015

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.